
Chinese drug discovery company founded on 28 April 2021 in Chengdu, Sichuan with 203.77 million yuan of registered capital, set up by researchers from the Chinese Academy of Sciences. Focuses on innovative medicines for metabolic disease, building a differentiated pipeline of oral small molecules for obesity, hypertension, type 2 diabetes and metabolic dysfunction-associated steatohepatitis. Its lead candidate VCT220 is an oral small molecule GLP-1 receptor agonist dosed once daily without food or water restrictions.
View Company Profile
Leave your rating